Display options
Cite
Liu Y, Wen H, Wu X, et al. The Bio-Persistence of Reversible Inflammatory, Histological Changes and Metabolic Profile Alterations in Rat Livers after Silver/Gold Nanorod Administration. Nanomaterials (Basel). 2021;11(10)doi: 10.3390/nano11102656.
Liu, Y., Wen, H., Wu, X., Wu, M., Liu, L., Wang, J., Huo, G., Lyu, J., Xie, L., & Dan, M. (2021). The Bio-Persistence of Reversible Inflammatory, Histological Changes and Metabolic Profile Alterations in Rat Livers after Silver/Gold Nanorod Administration. Nanomaterials (Basel, Switzerland), 11(10), . https://doi.org/10.3390/nano11102656
Liu, Ying, et al. "The Bio-Persistence of Reversible Inflammatory, Histological Changes and Metabolic Profile Alterations in Rat Livers after Silver/Gold Nanorod Administration." Nanomaterials (Basel, Switzerland) vol. 11,10 (2021). doi: https://doi.org/10.3390/nano11102656
Liu Y, Wen H, Wu X, Wu M, Liu L, Wang J, Huo G, Lyu J, Xie L, Dan M. The Bio-Persistence of Reversible Inflammatory, Histological Changes and Metabolic Profile Alterations in Rat Livers after Silver/Gold Nanorod Administration. Nanomaterials (Basel). 2021 Oct 09;11(10). doi: 10.3390/nano11102656. PMID: 34685095; PMCID: PMC8538332.
Copy Download .nbib Format: NLM
Share it on

Nanomaterials (Basel). 2021 Oct 09;11(10). doi: 10.3390/nano11102656.

The Bio-Persistence of Reversible Inflammatory, Histological Changes and Metabolic Profile Alterations in Rat Livers after Silver/Gold Nanorod Administration.

Nanomaterials (Basel, Switzerland)

Ying Liu, Hairuo Wen, Xiaochun Wu, Meiyu Wu, Lin Liu, Jiahui Wang, Guitao Huo, Jianjun Lyu, Liming Xie, Mo Dan

Affiliations

  1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, NCNST-NIFDC Joint Laboratory for Measurement and Evaluation of Nanomaterials in Medical Applications, Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, No. 11 Beiyitiao Zhongguancun, Haidian District, Beijing 100190, China.
  2. National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, No. 8 Hongda Mid-Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing 100176, China.
  3. CAS Key Laboratory of Standardization and Measurement for Nanotechnology, NCNST-NIFDC Joint Laboratory for Measurement and Evaluation of Nanomaterials in Medical Applications, Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, No. 11 Beiyitiao Zhongguancun, Haidian District, Beijing 100190, China.
  4. Department of Pathology, InnoStar Bio-Tech Nantong Co., Ltd., Nantong 226133, China.
  5. School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing 100049, China.
  6. The State Key Laboratory of New Pharmaceutical Preparations and Excipients, 226 Huanghe Road, Shijiazhuang 050035, China.

PMID: 34685095 PMCID: PMC8538332 DOI: 10.3390/nano11102656

Abstract

As a widely applied nanomaterial, silver nanomaterials (AgNMs) have increased public concern about their potential adverse biological effects. However, there are few related researches on the long-term toxicity, especially on the reversibility of AgNMs in vivo. In the current study, this issue was tackled by exploring liver damage after an intravenous injection of silver nanorods with golden cores (Au@AgNRs) and its potential recovery in a relatively long term (8 w). After the administration of Au@AgNRs into rats, Ag was found to be rapidly cleared from blood within 10 min and mainly accumulated in liver as well as spleen until 8 w. All detected parameters almost displayed a two-stage response to Au@AgNRs administration, including biological markers, histological changes and metabolic variations. For the short-term (2 w) responses, some toxicological parameters (hematological changes, cytokines, liver damages etc.) significantly changed compared to control and AuNRs group. However, after a 6-week recovery, all abovementioned changes mostly returned to the normal levels in the Au@AgNRs group. These indicated that after a lengthy period, acute bioeffects elicited by AgNMs could be followed by the adaptive recovery, which will provide a novel and valuable toxicity mechanism of AgNMs for potential biomedical applications of AgNMs.

Keywords: bio-persistence; liver toxicity; long-term toxicity; metabolic changes; recovery; silver nanomaterials

References

  1. Arch Pharm Res. 2011 Jan;34(1):153-8 - PubMed
  2. Nanotoxicology. 2014 Aug;8 Suppl 1:155-66 - PubMed
  3. Biomed Res Int. 2018 Jul 22;2018:8460910 - PubMed
  4. Mater Sci Eng C Mater Biol Appl. 2018 Dec 1;93:465-471 - PubMed
  5. Clin Cancer Res. 2014 Apr 15;20(8):2136-46 - PubMed
  6. Virchows Arch. 1996 Aug;428(6):353-65 - PubMed
  7. Part Fibre Toxicol. 2016 Feb 29;13:12 - PubMed
  8. Environ Pollut. 2017 Apr;223:395-402 - PubMed
  9. J Phys Chem B. 2005 Dec 1;109(47):22192-200 - PubMed
  10. Toxicol Appl Pharmacol. 2018 Oct 1;356:140-150 - PubMed
  11. Annu Rev Physiol. 2014;76:447-65 - PubMed
  12. Sci Rep. 2016 Feb 22;6:21827 - PubMed
  13. J Appl Toxicol. 2012 Nov;32(11):890-9 - PubMed
  14. Dalton Trans. 2017 Jul 11;46(27):8736-8745 - PubMed
  15. Toxicol Mech Methods. 2011 Jan;21(1):13-24 - PubMed
  16. J Appl Toxicol. 2015 Jun;35(6):681-93 - PubMed
  17. Science. 2006 Feb 3;311(5761):622-7 - PubMed
  18. Nanotoxicology. 2013 Aug;7(5):953-60 - PubMed
  19. Rev Environ Contam Toxicol. 2013;223:81-106 - PubMed
  20. ACS Nano. 2009 Feb 24;3(2):279-90 - PubMed
  21. Nanotoxicology. 2016 Sep;10(7):945-56 - PubMed
  22. Front Immunol. 2019 May 09;10:1009 - PubMed
  23. Int J Nanomedicine. 2012;7:1023-30 - PubMed
  24. Toxicol Sci. 2017 Oct 1;159(2):422-435 - PubMed
  25. Nanotoxicology. 2014 Sep;8(6):686-96 - PubMed
  26. J Biomed Nanotechnol. 2018 Nov 1;14(11):1953-1964 - PubMed
  27. J Control Release. 2006 Sep 12;114(3):343-7 - PubMed
  28. PLoS One. 2017 Sep 27;12(9):e0185554 - PubMed
  29. Arch Pharm Res. 2011 Feb;34(2):299-307 - PubMed
  30. Toxicol Sci. 2010 Nov;118(1):160-70 - PubMed
  31. Sci Rep. 2015 Jun 22;5:11398 - PubMed
  32. Arch Toxicol. 2018 Apr;92(4):1393-1405 - PubMed
  33. Ultrastruct Pathol. 2016;40(2):92-100 - PubMed
  34. Toxicol Lett. 2013 May 10;219(1):42-8 - PubMed
  35. Sci Rep. 2019 Dec 13;9(1):19131 - PubMed
  36. Bioanalysis. 2015;7(12):1527-44 - PubMed
  37. Biomaterials. 2013 Nov;34(33):8333-43 - PubMed
  38. PLoS One. 2014 Jan 24;9(1):e87179 - PubMed
  39. Small. 2005 Mar;1(3):325-7 - PubMed
  40. Biomaterials. 2010 Nov;31(32):8350-61 - PubMed
  41. Toxicol Sci. 2016 Mar;150(1):131-60 - PubMed
  42. J Toxicol Environ Health A. 2009;72(21-22):1279-84 - PubMed
  43. Anal Chem. 2012 Aug 7;84(15):6619-29 - PubMed
  44. Nanotoxicology. 2017 Jun;11(5):671-686 - PubMed
  45. Environ Toxicol Pharmacol. 2015 Nov;40(3):729-32 - PubMed
  46. Part Fibre Toxicol. 2016 Aug 24;13(1):48 - PubMed
  47. Clin Chim Acta. 2010 Dec 14;411(23-24):1841-8 - PubMed
  48. Nanomedicine (Lond). 2016 Jun;11(11):1359-75 - PubMed
  49. J Appl Toxicol. 2017 May;37(5):530-544 - PubMed
  50. Part Fibre Toxicol. 2010 Aug 06;7:20 - PubMed
  51. ACS Nano. 2012 Aug 28;6(8):7427-42 - PubMed
  52. Toxicol Lett. 2014 Aug 17;229(1):311-8 - PubMed
  53. Toxicol Sci. 2016 Apr;150(2):473-87 - PubMed
  54. J Appl Toxicol. 2012 Nov;32(11):920-8 - PubMed
  55. Small. 2014 Jan 29;10(2):385-98 - PubMed
  56. J Food Drug Anal. 2014 Mar;22(1):116-127 - PubMed
  57. Nanoscale. 2010 Aug;2(8):1489-93 - PubMed
  58. Reprod Toxicol. 2016 Apr;60:133-9 - PubMed
  59. Ageing Res Rev. 2008 Jan;7(1):1-7 - PubMed
  60. Int J Nanomedicine. 2010 Sep 07;5:653-9 - PubMed
  61. Toxicol In Vitro. 2010 Apr;24(3):872-8 - PubMed
  62. Metabolism. 2015 Nov;64(11):1426-34 - PubMed
  63. Nanomedicine. 2014 Nov;10(8):1757-66 - PubMed

Publication Types

Grant support